Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database.
David S LopezDanmeng HuangKonstantinos K TsilidisMohit KheraStephen B WilliamsRandall J UrbanOrestis A PanagiotouYong-Fang KuoJacques BaillargeonAlbert FariasTrudy KrausePublished in: Clinical endocrinology (2019)
Overall, increased use of TTh is inversely associated with PCa and this remained significant only among nondiabetics. These findings warrant further investigation in large randomized placebo-controlled trials to infer any health benefit by TTh.
Keyphrases
- placebo controlled
- prostate cancer
- double blind
- health insurance
- public health
- healthcare
- phase iii
- phase ii
- open label
- radical prostatectomy
- clinical trial
- health information
- replacement therapy
- randomized controlled trial
- stem cells
- phase ii study
- affordable care act
- radiation therapy
- climate change
- social media
- cell therapy
- drug induced
- locally advanced
- rectal cancer